Introduction
============

Malaria is an infectious disease that caused by *Plasmodium* species ([@B1]). *Plasmodium falciparum, P. vivax, P. malarie, P. ovale*, and *P. knowlesi* have been known as causes of human malaria ([@B2]--[@B3]). The most severe and deadly form of disease is caused by *P. falciparum* subspecies that causes the death of 1% of patients ([@B2]). According to WHO Malaria Report 2012, there was an approximately 219 million cases of malaria all around the world and 660,000 people died from this disease ([@B4]).

Nowadays after AIDS and tuberculosis, malaria is the most important human diseases. Unfortunately, despite using different methods for eradication or control of malaria, this disease is endemic in many tropical and subtropical countries (about 104 countries worldwide). Developing and spreading multidrug-resistant strains of *P. falciparum*, developing resistance in malaria vectors to the usual effective insecticides and unsuccessfulness in developing an effective and inexpensive vaccine are the most important reasons of failure in malaria eradication or control programs ([@B4]).

Today artemisinin-based combination therapy is the last defense against the malaria but there are some reports about the resistance against atremisinin and its derivatives ([@B5]). Furthermore, these drugs are too expensive for widespread use ([@B6]). Therefore, we need effective and inexpensive drugs to replace chloroquine, which was the main stay of chemotherapy of malaria for more than 50 years.

Aurones (2-benzylidenbenzofuran-3(2H)-ones), are secondary metabolite belonging to the flavonoids family and have an important role for the pigmentation of flowers in which they are found ([@B7]). They are structural isomers of flavones and there are reports about their inhibitory effects on erythrocytic stages of *P. falciparum* strains in vitro ([@B8]--[@B10]). Other effects of aurones are antileshmanial ([@B11]--[@B12]), trypanocidal ([@B13]), antiviral, and antifungal effects ([@B7]).

The aim of this study was to investigate aurones analogs in order to find new drug candidates against malaria.

Materials and Methods
=====================

Chemicals
---------

Reagents and materials obtained from Merck (Darmstadt, Germany) and Sigma Aldrich (Steinheim, Germany), and DMSO was purchased from Fluka (Steinheim, Germany) and RPMI 1640 medium from Gibco-Invitrogen (Paisley, Scotland, UK).

Tested compounds
----------------

Synthesis of these compounds has been described previously ([@B10], [@B14]--[@B15]). The basic structure of aurones derivatives is indicated in [Fig. 1](#F1){ref-type="fig"}. The structures of synthesized aurones have been shown in [Table 1](#T1){ref-type="table"}.

###### 

the structure of synthesized aurones derivatives

  **Compound**   **R~1~**   **R~2~**   **R~3~**   **R~4~**   **R~5~**
  -------------- ---------- ---------- ---------- ---------- ----------
  M1             OMe        OMe        OMe        OMe        Br
  M2             OMe        OMe        OMe        OMe        OMe
  M3             OMe        OMe        \-         OMe        OMe
  M4             OMe        OMe        OMe        OH         Cl
  M5             OMe        OMe        OMe        OH         Br
  M6             OMe        OMe        OMe        OEt        Br
  M7             OMe        OMe        OMe        OPr        Br
  M8             \-         \-         OMe        OMe        Cl
  M9             \-         \-         OMe        OMe        Br
  M10            \-         \-         OMe        OH         Cl
  M11            \-         \-         OMe        OH         Br

![Basic structures of aurones derivatives](IJPA-11-371-g001){#F1}

Parasite Culture
----------------

The *P. falciparum* strain used in this study was 3D7 chloroquine (CQ) sensitive. In vitro culture of *P. falciparum* was carried out according to the method described by Trager and Jensen with some modifications ([@B16]--[@B18]). Parasites were maintained in continuous culture on human erythrocytes (blood group O^+^), provided by the Blood Transfusion Organization (Zanjan, Iran), in RPMI 1640 medium with 5% of human AB^+^ serum, 0.3 g/100 mL Albumax I, 25 mM HEPES, 19 mM sodium carbonate and 30 μg/mL gentamicin sulfate at pH 7.2. The growth medium was replaced daily, and cultures were gassed with a mixture of 91% N~2~, 6% CO~2~, and 3% O~2~. Synchronization to the ring stage was achieved by sorbitol method ([@B19]).

In vitro antimalarial tests
---------------------------

Compounds were prepared in DMSO at concentration of 10 mg/mL and serially diluted with culture medium to reach 1mg/mL before use. Twenty μL of 2-fold dilution series (50 -- 0.3906 μg/mL) of compounds prepared in assay medium and added to each well of 96-well plates in triplicate. One hundred eighty μL of synchronous *P. falciparum* culture (1% parasitemia and 2% hematocrit) added to each well reaching a final volume of 200 μL per well. Plates were incubated at 37° C for 24 h. Chloroquine was used as positive control and parasitized erythrocytes without drug were used as negative control. After 24 h incubation, Giemsa stained thin smears were made and parasitemia was confirmed by the numeration of 1000 erythrocytes ([@B20]). Data were imported in SPSS 16.0 software and IC~50~ values were calculated by means of Finney's Probit analysis ([@B21]).

In vitro cytotoxicity assay
---------------------------

The toxic effects of active compounds against *P. falciparum* were assessed on human breast cancer cell lines (MCF7 and T47D) by using MTT (3--\[4, 5-dimethylthiazol-2-yl\] -2, 5 diphenyltetrazolium bromide) assay ([@B22]--[@B23]) and results were compared with untreated control. The cells were cultured in RPMI 1640 medium containing 10% FBS (Fetal Bovine Serum) and incubated at 37° C with 5% CO~2~ and 96% humidity. After several subcultures, cells were distributed in 96-well plates at 1,000 cells in 100 μL of culture medium and incubated for 24 h at same condition to allow attachment of cells to the bottom of wells. Then culture medium removed and 100 μL of the same medium containing the drugs at various concentrations (100, 30, 10, 3, 1, 0.1 μM) added to each well in triplicate. Plates further incubated for 5 days in same condition. The last column of plate containing 1000 cells in100 μL of culture medium was regarded as control. After 5 days incubation the drug-containing medium discharged. For evaluation of cell survival, 25 μL of MTT solution (4 mg/mL in PBS) added to each well and plates incubated for 3 h (in same condition). Then 100 μL of DMSO added to each well and plates were gently shaken to dissolve the formed formazan crystals. The absorbance of each well measured at 540 nm using an ELISA plate reader (Infinite M200, Tecan). The GI% (Growth Inhibition percent) was calculated using the formula; %Growth Inhibition = 100 − (OD~test~ − OD~control~) × 100, where OD~test~ is the mean absorbance of treated cells and OD~control~ is the mean absorbance of a negative control. The cell survival of control assumed 100% and IC~50~values generated from dose-response curves for each cell line.

Results
=======

In vitro antiplasmodial activity
--------------------------------

All the 11 compounds screened for in vitro antiplasmodial activity against the CQ-sensitive (3D7) *P. falciparum* strain ([Table 2](#T2){ref-type="table"}). Of 11 compounds tested, 3 compounds had better antiplasmodial activity. Compound M7 showed significant antiplasmodial activity with IC~50~ value of 2.3 μM. Compounds M3 and M6 also showed good antiplasmodial activity with IC~50~ values of 7.82 and 7.27 μM respectively. The rest of compounds did not show noticeable antiplasmodial activity.

###### 

Antiplasmodial activity and toxicity assessment of tested compounds

  **Compound**   ***P. falciparum* IC~50~ (μM)**   **MCF7 IC~50~ (μM)**   **T47D IC~50~ (μM)**   **SI for MCF7**   **SI for T47D**
  -------------- --------------------------------- ---------------------- ---------------------- ----------------- -----------------
  M1             22.29                             36.34                  28.85                  1.63              1.29
  M2             ≥50                               \-                     \-                     \-                \-
  M3             7.82                              20.80                  3.15                   2.65              0.4
  M4             ≥50                               \-                     \-                     \-                \-
  M5             28.64                             34.75                  19.39                  1.21              1.21
  M6             7.27                              29.90                  9.35                   4.11              1.28
  M7             2.3                               17.19                  11.65                  7.47              5.06
  M8             22.04                             20.60                  9.07                   0.93              0.41
  M9             32.32                             34.99                  29.47                  1.08              0.91
  M10            36.38                             20.27                  11.72                  0.55              0.55
  M11            ≥50                               \-                     \-                     \-                \-
  CQ             0.775                             \-                     \-                     \-                \-

In vitro cytotoxicity assay
---------------------------

Cytotxicity of compounds with IC~50~ value less than 50 μM assessed on MCF7 and T47D cell lines. Results of toxicity activity of the tested compounds and selectivity index (SI) are shown in [Table 2](#T2){ref-type="table"}. The SI is defined as the ratio of the toxicity to the antiplasmodial activity and the higher selectivity should offer the potential of safer therapy.

The M7 compound had high selectivity for *P. falciparum* than studied cell lines in comparison with other compounds (*P* = 0.008).

Discussion
==========

Several studies have been done concerning the aurones as chemotherapeutic antimalarial agents ([@B8]--[@B10]). Aurones \[2-benzylidenebenzofuran-3(2H)-ones\] are natural compounds belong to the flavonoids family. The natural entity of aurones, their inhibitory activity on *Leishmania* and malaria parasites ([@B8], [@B24]--[@B25]), has prompted us to investigate aurones analogs in order to gather more structural elements required for the antiplasmodial activity.

Three out of 11 compounds (M3, M6 and M7) showed good antiplasmodial activity with IC~50~ values of 7.82, 7.27 and 2.3 μM against 3D7 starin of *P. falciparum* respectively. The M7 compound had better selectivity index than other two active compound (with SI value of 7.47 and 5.06 for MCF7 and T47D cell lines respectivly). This let us believe that activity obtained with this compound is not due to general toxicity against *P. falciparum* but can be explained by specific anti-plasmodial activity andshould offer potential for safer therapy.

In one study a library comprising 44 different substituted aurones derivatives was synthesized and screened against the chloroquine resistant *P. falciparum* W2 strain and demonstrated that some compounds showed anti-plasmodial activity in micromolar range ([@B10]). "A series of naturally occurring aurones was synthesized and evaluated for their ability to inhibit erythrocytic stages of *P. falciparum* strains in vitro*"* ([@B8]). The most active compound was 4,6,4′-triacetyl-3′,5′-dimethoxy-2-aurone with IC~50~ values of 0.007 μM and 0.18 μM for the *P. falciparum* strains K1 and NF54, respectively.

According to previous investigations, the structure activity relationship confirmed that methoxylation at 4 and 6 carbons were beneficial for antiplasmodial activity of aurones derivatives ([@B9]). In our study, these substitutions were confirmed (compound M1 versus M9 and M5 versus M11). This substitution pattern involved in binding of aurones derivatives to protozoal target protein ATP-binding cassette (ABC) transporters like P-glycoprotein ([@B26]--[@B27]). At the ring B, presence of a hydrophobic group was highly beneficial for antiplasmodial effect as illustrated by comparing derivatives M6 versus M5 and M9 versus M11. The elongation of chain from methoxy to ethoxy and then to propoxy leads to an increase in anti-plasmodial effect (compound M1 versus M6 and M7). The presence of a hydrophobic halogen atom at the ring B at 5 positions was quite beneficial as illustrated by comparing derivatives M1 and M2. In conclusion, throughout the present study, we report the preliminary results regarding the structural requirements for the antiplasmodial activity of aurones. We have found that the replacement of the 4 and 5 positions at ring B with propoxyand bromide (Br) respectively was revealed to be highly advantageous for the activity. We also optimized (at least in part) the nature of substituents to be present at the A and B-rings.

Conclusion
==========

The present results bring essential elements, which will be used, for the synthesis of more active aurones against malaria parasite. Further studies need to confirm the in vivo antiplasmodial properties of active aurones derivatives against rodent malaria.
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